The SAFE Prospective Registry

ConditionAtrial Fibrillation, Paroxysmal or Persistent

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorUniversity Hospital Ostrava

About this trial

Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Atrial fibrillation (Afib); (paroxysmal, persistent)

Patients indicated for catheter ablation and/or electrical cardioversion

Signed informed consent

Disqualifiers

Longstanding or permanent atrial fibrillation

Severe mitral regurgitation

Heart failure with a permanently reduced ejection fraction

Cerebral ischaemic stroke in < 3 months

Trial design

Design model

Single group

Treatments tested in this trial

Catheter ablation and/or electrical cardioversion
Procedure/Surgery
Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.

Treatment groups

60 Participants

are divided into 1 treatment group

Group A: Catheter ablation and/or electrical cardioversionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Atrial fibrillation recurrence based on secretoneurin levels

Atrial fibrillation recurrence based on secretoneurin levels will be assessed

Time frame

24 months

Secondary outcomes

Brain injury detection

Brain injury will be detected using serum protein S100B and neuron specific enolase.

Time frame

24 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital Ostrava

Lead sponsor

Source ClinicalTrials.gov

Apply now